Myasthenia Gravis

A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.

Also Known As:

Myasthenia Gravis, Generalized; Myasthenia Gravis, Ocular; Anti MuSK Myasthenia Gravis; Generalized Myasthenia Gravis; Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis; Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis; Myasthenia Gravis, Anti-MuSK; Myasthenia Gravis, MuSK; Ocular Myasthenia Gravis; Anti-MuSK Myasthenia Gravis; MuSK MG; MuSK Myasthenia Gravis; Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis; Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis

Neoplasms: 1324753
- Paraneoplastic Syndromes: 1065
  - Nervous System Paraneoplastic Syndromes: 125
    - Myasthenia Gravis: 8555
- Neoplasms by Site: 4
  - Nervous System Neoplasms: 235
    - Nervous System Paraneoplastic Syndromes: 125
      - Myasthenia Gravis: 8555
Nervous System Diseases: 14178
- Neurodegenerative Diseases: 42472
  - Nervous System Paraneoplastic Syndromes: 125
    - Myasthenia Gravis: 8555
- Neuromuscular Diseases: 2005
  - Neuromuscular Junction Diseases: 83
    - Myasthenia Gravis: 8555
- Autoimmune Diseases of the Nervous System: 1461
  - Myasthenia Gravis: 8555
Immune System Diseases: 4321
- Autoimmune Diseases: 34618
  - Autoimmune Diseases of the Nervous System: 1461
    - Myasthenia Gravis: 8555

Khaled Al Kattan Selected Research

Khaled Al Kattan Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure